Connect with us

Uncategorized

Gardin raises $1.2M pre-seed to use ‘optical phenotyping’ tech to improve food production

Published

on

Gardin, a ‘deep tech’ hardware and software startup developing optical phenotyping technology and analytics to optimise food production, has raised $1.2 million in pre-seed funding.

Leading the round is LDV Capital, with participation from Seedcamp, and MMC Ventures. A number of angel investors are also investing, including Pratima Aiyagari, Gilad Engel, and Abdulaziz Alrashed.

Founded in late 2019, Gardin’s mission, in the U.K. company’s own words, is to help everyone access high quality, nutritious food that is “good for you and for our planet”.

Specifically, the startup is developing tech for farms based on its own “optical phenotyping” hardware and accompanying analytics software. The idea is to enable food producers to measure and monitor the nutritional value of food, from “seed to plate in a real world environment,” rather than a lab.

“With deployment of Gardin’s OS, insight from our analytics will be delivered to help food producers optimise production, grow nutritious food, lower carbon footprint and reduce waste,” says founder and CEO Sumanta Talukdar. “At Gardin, we want to empower food producers to feed the world consciously, sustainably and nutritionally, as it should be”.

Talukdar says he started the company after learning that the traditional food industry currently “does not, or cannot, quantifiably measure food nutrition and quality”. This has seen Gardin partner with some of the leading crop and plant physiologists, phenotyping experts and plant scientists to identify the key biochemical mechanisms in various crops related to plant physiology.

“By designing hardware to specifically measure the signatures of these mechanisms, Gardin is able to quantify plant physiology and key compounds density with high fidelity (i.e. signal/noise ratio) at a cost similar to consumer electronics goods,” he explained. To achieve this, Gardin is employing a multispectral data fusion approach, using a suite of remote sensing and computer vision techniques to capture very specific data which is then “fused” to drive the analytics.

To that end, Gardin has been designed to assist both traditional and CEA (controlled environment agriculture), with the ambitious aim to become the new “food production gold standard”.

“Our full stack product is designed to run and optimise the entire growing environment running silently in the background like an OS i.e we are solving their problems, helping food producers grow higher quality food and reducing their operating costs and carbon footprint,” adds Talukdar.

“We have also designed our platform so we can integrate with their existing architectures. To us, asking a producer in what is already an asset heavy industry to change or add to their system to make us fit, was folly”.

In terms of traction, Talukdar says Gardin has already secured pilot trials that are ready to go live early this year with “key go-to-market clients. They include supermarket chains, food producers and vertical farms.

Lyron Foster is a Hawaii based African American Musician, Author, Actor, Blogger, Filmmaker, Philanthropist and Multinational Serial Tech Entrepreneur.

Continue Reading
Comments

Uncategorized

How Rani Therapeutics’ robotic pill could change subcutaneous injection treament

Published

on

A new auto-injecting pill might soon become a replacement for subcutaneous injection treatments.

The idea for this so-called robotic pill came out of a research project around eight years ago from InCube Labs—a life sciences lab operated by Rani Therapeutics Chairman and CEO Mir Imran, who has degrees in electrical and biomedical engineering from Rutgers University. A prominent figure in life sciences innovation, Imran has founded over 20 medical device companies and helped develop the world’s first implantable cardiac defibrillator.

In working on the technology behind San Jose-based Rani Therapeutics, Imran and his team wanted to find a way to relieve some of the painful side effects of subcutaneous (or under-the-skin) injections, while also improving the treatment’s efficacy. “The technology itself started with a very simple thesis,” said Imran in an interview. “We thought, why can’t we create a pill that contains a biologic drug that you swallow, and once it gets to the intestine, it transforms itself and delivers a pain-free injection?”

Rani Therapeutics’ approach is based on inherent properties of the gastrointestinal tract. An injecting mechanism in their pill is surrounded by a pH-sensitive coating that dissolves as the capsule moves from a patient’s stomach to the small intestine. This helps ensure that the pill starts injecting the medicine in the right place at the right time. Once there, the reactants mix and produce carbon dioxide, which in turn inflates a small balloon that helps create a pressure difference to help inject the drug-loaded needles into the intestinal wall. “So it’s a really well-timed cascade of events that results in the delivery of this needle,” said Imran.

Despite its somewhat mechanical procedure, the pill itself contains no metal or springs, reducing the chance of an inflammatory response in the body. The needles and other components are instead made of injectable-grade polymers, that Imran said has been used in other medical devices as well. Delivering the injections to the upper part of the small intestine also carries little risk of infection, as the prevalence of stomach acid and bile from the liver prevent bacteria from readily growing there.

One of Imran’s priorities for the pill was to eliminate the painful side effects of subcutaneous injections. “It wouldn’t make sense to replace them with another painful injection,” he said. “But biology was on our side, because your intestines don’t have the kind of pain sensors your skin does.” What’s more, administering the injection into the highly vascularized wall of the small intestine actually allows the treatment to work more efficiently than when applied through subcutaneous injection, which typically deposits the treatment into fatty tissue.

Imran and his team have plans to use the pill for a variety of indications, including the growth hormone disorder acromegaly, diabetes, and osteoporosis. In January 2020, their acromegaly treatment, Octreotide, demonstrated both safety and sustained bioavailability in primary clinical trials. They hope to pursue future clinical trials for other indications, but chose to prioritize acromegaly initially because of its well-established treatment drug but “very painful injection,” Imran said.

At the end of last year, Rani Therapeutics raised $69 million in new funding to help further develop and test their platform. “This will finance us for the next several years,” said Imran. “Our approach to the business is to make the technology very robust and manufacturable.”

Continue Reading

Uncategorized

Address cybersecurity challenges before rolling out robotic process automation

Published

on

Robotic process automation (RPA) is making a major impact across every industry. But many don’t know how common the technology is and may not realize that they are interacting with it regularly. RPA is a growing megatrend — by 2022, Gartner predicts that 90% of organizations globally will have adopted RPA and its received over $1.8 billion in investments in the past two years alone.

Due to the shift to remote work, companies across every industry have implemented some form of RPA to simplify their operations to deal with an influx of requests. For example, when major airlines were bombarded with cancellation requests at the onset of the pandemic, RPA became essential to their customer service strategy.

Throughout 2021, security teams will begin to realize the unconsidered security challenges of robotic process automation.

According to Forrester, one major airline had over 120,000 cancellations during the first few weeks of the pandemic. By utilizing RPA to handle the influx of cancellations, the airline was able to simplify its refund process and assist customers in a timely matter.

Delivering this type of streamlined cancellation process with such high demand would have been extremely challenging, if not impossible, without RPA technology.

The multitude of other RPA use cases that have popped up since COVID-19 have made it evident that RPA isn’t going away anytime soon. In fact, interest in the usage of RPA is at an unprecedented high. Gartner inquiries related to RPA increased over 1,000% during 2020 as companies continue to invest.

However, there’s one big issue that’s commonly overlooked when it comes to RPA — security. Like we’ve seen with other innovations, the security aspect of RPA isn’t implemented in the early stages of development — leaving organizations vulnerable to cybercriminals.

If the security vulnerabilities of RPA aren’t addressed quickly, there will be a string of significant RPA breaches in 2021. However, by realizing that these new “digital coworkers” have identities of their own, companies can secure RPA before they make the headlines as the latest major breach.

Understanding RPA’s digital identity

With RPA, digital workers are created to take over repetitive manual tasks that have been traditionally performed by humans. Their interaction directly with business applications mimics the way humans use credentials and privilege — ultimately giving the robot an identity of its own. An identity that is created and operates much faster than any human identity but doesn’t eat, sleep, take holidays, go on strike or even get paid.

Continue Reading

Uncategorized

Eco raises $26M in a16z-led round to scale its digital cryptocurrency platform

Published

on

‍Eco, which has built out a digital global cryptocurrency platform, announced Friday that it has raised $26 million in a funding round led by a16z Crypto.

Founded in 2018, the SF-based startup’s platform is designed to be used as a payment tool around the world for daily-use transactions. The company emphasizes that it’s “not a bank, checking account, or credit card.”

“We’re building something better than all of those combined,” it said in a blog post. The company’s mission has also been described as an effort to use cryptocurrency as a way “to marry savings and spending,” according to this CoinList article.

Eco users can earn up to 5% annually on their deposits and get 5% cashback on when transacting with merchants such as Amazon, Uber, and others. Next up: the company says it will give its users the ability to pay bills, pay friends and more “all from the same, single wallet.” That same wallet, it says, rewards people every time they spend or save.

After a “successful” alpha test with millions of dollars deposited, the company’s Eco App is now available to the public.

A slew of other VC firms participated in Eco’s latest financing, including Founders Fund, Activant Capital, Slow Ventures, Coinbase Ventures, Tribe Capital, Valor Capital Group, and more than one hundred other funds and angels.  Expa and Pantera Capital co-led the company’s $8.5 million funding round.

CoinList co-founder Andy Bromberg stepped down from his role last fall to head up Eco. The startup was originally called Beam before rebranding to Eco “thanks to involvement by founding advisor, Garrett Camp, who held the Eco brand,” according to Coindesk. Camp is an Uber co-founder and Expa is his venture fund.

For a16z Crypto, leading the round is in line with its mission.

In a blog post co-written by Katie Haun and Arianna Simpson, the firm outlined why it’s pumped about Eco and its plans.

“One of the challenges in any new industry — crypto being no exception — is building things that are not just cool for the sake of cool, but that manage to reach and delight a broad set of users,” they wrote. “Technology is at its best when it’s improving the lives of people in tangible, concrete ways…At a16z Crypto, we are constantly on the lookout for paths to get cryptocurrency into the hands of the next billion people. How do we think that will happen? By helping them achieve what they already want to do: spend, save, and make money — and by focusing users on tangible benefits, not on the underlying technology.”

Eco is not the only crypto platform offering rewards to users. Lolli gives users free bitcoin or cash when they shop at over 1,000 top stores.


Early Stage is the premier “how-to” event for startup entrepreneurs and investors. You’ll hear firsthand how some of the most successful founders and VCs build their businesses, raise money and manage their portfolios. We’ll cover every aspect of company building: Fundraising, recruiting, sales, product-market fit, PR, marketing and brand building. Each session also has audience participation built-in — there’s ample time included for audience questions and discussion.


Continue Reading

Trending